Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)

This prospective observational cohort (n=36) assesses brain activity via EEG before, during and after intramuscular ketamine administered as standard of care for treatment-resistant major depressive disorder; genetic markers will also be collected to explore associations with response.

Participants are patients aged 21–60 receiving IM ketamine at the study site (up to 10 sessions). EEG measurements, clinical rating scales (including MADRS), and a genetic cheek swab will be used to inform future ketamine study designs.